Skip to content
Screener

Retained Earnings at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.32B+25.8%
Amgen logo
AmgenAMGN
-$22.28B+13.4%
WHW
Whitehawk TherapeuticsWHWK
-$375.44M-44.6%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
-$514.1M-28.0%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$648.67M-19.8%
Eikon Therapeutics, Inc. logo
Eikon Therapeutics, Inc.EIKN
-$1B

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.49B+68.5%
Enterprise value$3.36B+69.4%
P/S15×+10.3×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206357
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value, 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 87,856,154 and 87,796,561 shares issued and outstanding as of March 31, 2026 and December 31, 202599
Additional paid-in capital1,772,8301,757,197
Accumulated other comprehensive (loss) income(494)2,267
Accumulated deficit(835,078)(736,539)
Total stockholders’ equity937,2671,022,934
Total liabilities and stockholders’ equity$1,030,348$1,109,324

Item 1. Financial Statements (UNAUDITED).

FAQ

What is IDEAYA Biosciences, Inc.'s retained earnings?
IDEAYA Biosciences, Inc. (IDYA) reported retained earnings of -$835.08M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s retained earnings changed year-over-year?
IDEAYA Biosciences, Inc.'s retained earnings decreased by 20.2% year-over-year, from -$695.02M to -$835.08M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s retained earnings?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s retained earnings has grown at a 42.1% compound annual growth rate (CAGR), from -$126.99M to -$736.54M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about IDEAYA Biosciences, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude